No 10Y consistency score yet for revenue — the year-earlier revenue was zero, negative or too small a base to compare against in 22 of the 40 quarters in the window, leaving 18 comparable quarters; at least 28 are needed.
Valuation vs own 10Y history: P/S N/A · No P/S — trailing revenue unavailable or non-positive.
Annualized revenue (TTM) · by quarter, last 40
Quarterly YoY revenue growth vs the 20% line
P/S multiple vs its 10Y median
The latest delayed quote for HeartBeam, Inc. (BEAT) stock was $0.65 as of Oct 5, 2026, 4:00 PM EDT, up 50.53% from the previous close.
Longer view (total return, dividends reinvested): past 12 months -66.3% · 3-year avg -30.5%/yr
HeartBeam, Inc. is a development stage company, which engages in cardiovascular diagnostic technology.
Medical - Specialties · Santa Clara, CA
Selected amounts supplied by FMP for each displayed period. Reviewed label references appear where available; other labels are unverified, and items may overlap.
2019-12-31 · USD
Reviewed labels link to their filing; other labels are unverified FMP source labels.
Reviewed presentation labels and parent/child details link to filing evidence; other FMP source labels remain unverified. Mutual exclusivity and reconciliation to a total for the same reporting period and currency have not been verified; percentages and stacked totals are unavailable.
Next Earnings Date
Nov 12, 2026
37 days away
EPS Estimate
-0.09
Revenue Est.
$75000.00
Last Quarter Results
EPS
$-0.10
vs Estimate
$-0.09
Revenue
| Stock | Market Cap | Close Price | Price Change | TTM Total Return | 5Y CAGR | 10Y CAGR | Compare |
|---|---|---|---|---|---|---|---|
| 1BEAT | $36.31M | $0.65 | +50.53% | -66.28% | N/A | N/A | N/A |
| 2ELUT | $36.32M | $0.82 | +5.51% | -6.61% | -33.96% | N/A | vs BEAT |
| 3BCTX | $36.37M | $4.18 | +3.47% | -67.87% | -67.32% | -52.81% | vs BEAT |
| 4DCGO | $36.05M | $0.36 | -1.22% | -71.09% | -48.40% | N/A | vs BEAT |
| 5ELTX | $36.61M | $1.92 | +0.00% | -82.46% | N/A | N/A | vs BEAT |
| 6ARAY | $35.89M | $0.30 | +7.37% | -82.00% | -39.94% | -25.77% | vs BEAT |
forward FY estimate
N/A
$100000.00
vs Estimate
$147400.00
Consensus Rating
Based on 2 analysts
Average Price Target
$3.50
+435.0% upside
Low
$2.00
Current
$0.65
High
$5.00
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $-0.23 | $-0.09 | $0.00 | 2 |
| Quarter ending Dec 2026 | $-0.22 | $-0.09 | $0.00 | 2 |
| Quarter ending Mar 2027 | $-0.19 | $-0.07 | $0.00 | 1 |
| Quarter ending Jun 2027 | $-0.17 | $-0.07 | $0.00 | 1 |
Annual
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| FY 2026 | $-0.66 | $-0.38 | $-0.08 | 2 |
| FY 2027 | $-0.49 | $-0.29 | $-0.06 | 2 |
Quarterly
| Period | Low | Avg | High | # Analysts |
|---|---|---|---|---|
| Quarter ending Sep 2026 | $17307.00 | $75000.00 | $166785.00 | 2 |
| Quarter ending Dec 2026 | $46154.00 | $200000.00 | $444761.00 | 2 |
| Quarter ending Mar 2027 | $46154.00 | $200000.00 | $444761.00 | 1 |
| Quarter ending Jun 2027 | $92308.00 | $400000.00 | $889522.00 | 1 |
Annual
| Period |
|---|
Source: FMP Analyst Consensus Estimates. Forward P/E is unavailable for the current price and estimate observations.
| Low |
|---|
| Avg |
|---|
| High |
|---|
| # Analysts |
|---|
| FY 2026 | $108633.00 | $275000.00 | $428641.00 | 2 |
| FY 2027 | $1.47M | $3.73M | $5.82M | 2 |
